Table 2 Patient characteristics and relationships between ERβ1 and clinicopathologic factors
Variables | ERβ1-Negative | ERβ1-Positive | r P | ||
|---|---|---|---|---|---|
No. of patients (n =56) | % | No. of patients (n = 26) | % | ||
Age(years) | −0.036 0.749 | ||||
≤48 | 28 | 50.00 | 14 | 53.85 | |
>48 | 28 | 50.00 | 12 | 46.15 | |
Tumor size(cm) | 0.009 0.936 | ||||
≤2 | 22 | 39.29 | 10 | 38.46 | |
2–5 | 32 | 57.14 | 15 | 57.69 | |
>5 | 2 | 3.57 | 1 | 3.85 | |
Metastatic lymph nodes | −0.368 0.001* | ||||
Negative | 15 | 26.79 | 17 | 65.38 | |
Positive | 41 | 73.21 | 9 | 34.62 | |
AR | 0.309 0.005* | ||||
Negative | 48 | 85.71 | 15 | 57.69 | |
Positive | 8 | 14.29 | 11 | 42.31 | |
ZEB1 | −0.330 0.003* | ||||
Negative | 19 | 33.93 | 18 | 69.23 | |
Positive | 37 | 66.07 | 8 | 30.77 | |
E-cadherin | 0.391 0.0001* | ||||
Negative | 47 | 83.93 | 12 | 46.15 | |
Positive | 9 | 16.07 | 14 | 53.85 | |